Verily has received a 510(k) clearance from the FDA for its own clinical study smartwatch, complete with an on-demand ECG.
Telehealth equipment maker Tyto Care raised an extra $9 million through its series C round, bringing its total up to $33.5 million.
Abbott has exercised a three-year-old option to purchase Cephea Valve Technologies, a developer of mitral heart valve replacements.
Apple and J&J are teaming up to see if the Apple Watch can help catch and diagnose seniors with atrial fibrillation earlier and faster than before.
Proteus Digital Health launched a smart chemotherapy pill that aims to help oncologists track effectiveness and adherence in their cancer patients.
Fitbit and the NIH have launched a bring-your-own-device project for participants in the All of Us research program.
Roche launched its uPath software for digital pathology, billing it as an improvement in speed and performance over its previous version.
Brainsway, developer of transcranial magnetic device treatments for depression and OCD, plans to raise $30 million through a Nasdaq IPO.
The FDA plans to hire at least 50 reviewers for cell and gene therapies ahead of what it describes as a surge of products entering development.
Abbott received FDA approval for its Amplatzer Piccolo Occluder, which it describes as the world’s first implant for babies as little as two pounds.
